Pharmaceutical compound
Clinical data | |
---|---|
Other names | β-Naltrexamine; 6β-Aminonaltrexol; 6β-Amino-17-(cyclopropylmethyl)-4,5α-epoxymorphinan-3,14-diol |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H26N2O3 |
Molar mass | 342.439 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
β-Naltrexamine, or 6β-naltrexamine, is an opioid receptor antagonist related to naltrexol and naltrexone. It has served as a parent pharmacophore for irreversible antagonists of the μ-opioid receptor (MOR) such as β-chlornaltrexamine (β-CNA) and β-funaltrexamine (β-FNA). Naltrexamine itself is a neutral antagonist of the MOR and the δ-opioid receptor (DOR) with similarly high affinity for both receptors.
References
- ^ Fulton BS (2014). Drug Discovery for the Treatment of Addiction: Medicinal Chemistry Strategies. Wiley. p. 220. ISBN 978-1-118-88957-2. Retrieved 14 September 2024.
- ^ Testa B (2013). Advances in Drug Research. ISSN. Elsevier Science. p. 184. ISBN 978-1-4832-8798-0. Retrieved 14 September 2024.
- ^ Wang D, Raehal KM, Bilsky EJ, Sadée W (June 2001). "Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence". J Neurochem. 77 (6): 1590–1600. doi:10.1046/j.1471-4159.2001.00362.x. PMID 11413242.
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |